Results 51 to 60 of about 60,343,578 (236)

The added value of ordinal analysis in clinical trials: an example in traumatic brain injury. [PDF]

, 2011
INTRODUCTION: In clinical trials, ordinal outcome measures are often dichotomized into two categories. In traumatic brain injury (TBI) the 5-point Glasgow outcome scale (GOS) is collapsed into unfavourable versus favourable outcome.
Perel, P, Steyerberg, Ewout W, IMPACT (International Mission on Prognosis and Clinical Trial De, Edwards, P. (Phil), Steyerberg, Ewout, Ewout W Steyerberg, Phil Edwards, Perel, P. (Pablo), Lingsma, Hester F., Murray, G.D. (Gordon), Steyerberg, Ewout W., Roozenbeek, Bob, Lingsma, Hester F, Gordon D Murray, Andrew IR Maas, Edwards, P, Maas, AIR (Arne), Roberts, I. (Ian), CRASH (Corticosteroid Randomisation After Significant Head Injur, Roberts, Ian, Perel, Pablo, Murray, Gordon D, Maas, A.I.R. (Andrew), ?, ?, Ian Roberts, Maas, Andrew Ir, null null, Edwards, Phil, Steyerberg, E.W. (Ewout), Hester F Lingsma, Murray, Gordon D., Pablo Perel, Roozenbeek, B. (Bob), Murray, GD, Bob Roozenbeek, Maas, Andrew I.R., Lingsma, Hester, Roberts, I   +37 more
core   +2 more sources

Implementation of microbiota analysis in clinical trials for cystic fibrosis lung infection: experience from the OligoG phase 2b clinical trials

, 2021
Culture-independent microbiota analysis is widely used in research and being increasingly used in translational studies. However, methods for standardisation and application of these analyses in clinical trials are limited.
Conway, Joy H, Weiser, Rebecca, Rye, Philip D., OligoG phase 2b clinical trials group, Mahenthiralingam, Eshwar, Carroll, Mary   +5 more
core   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Dose selection in seamless phase II/III clinical trials based on efficacy and toxicity [PDF]

Seamless phase II/III clinical trials are attractive in development of new drugs because they accelerate the drug development process. Seamless phase II/III trials are carried out in two stages.
Kimani, Peter K.
core  

Clinical trials profile: Professionals and sites

, 2010
Clinical trial is considered a breakthrough method in medicine and essential to the development of new drugs. Clinical trials that comply with international and national regulations require an appropriate infrastructure and team qualification.
Marcelo E. Nita, Flair J. Carrilho, ONO-NITA, Suzane Kioko, BARBOSA, Fernanda R., Helena S. Paschoale, NITA, Marcelo E., Fernanda R. Barbosa, CARRILHO, Flair J., Suzane Kioko Ono-Nita, PASCHOALE, Helena S.   +9 more
core   +1 more source

Statistical analysis of the primary outcome in acute stroke trials [PDF]

, 2012
Common outcome scales in acute stroke trials are ordered categorical or pseudocontinuous in structure but most have been analyzed as binary measures. The use of fixed dichotomous analysis of ordered categorical outcomes after stroke (such as the modified
Lees, K.R., Saver, J.L., Howard, G., TONI, Danilo, Altman, H., Schellinger, P.D., Bland, M., Hogg, C., Bath, P.M.W., European Stroke Organisation Outcomes Working Group   +9 more
core   +1 more source

Effect of glycemic control and type of diabetes treatment on TB treatment outcomes among people with TB-diabetes: A systematic review (updated August 2024).

PLoS ONE
BackgroundStringent glycemic control and/or using insulin either as a replacement for or in addition to oral hypoglycemic agents (OHAs) has been recommended for people with tuberculosis and diabetes mellitus (TB-DM). This systematic review (PROSPERO 2016:
Hemant Deepak Shewade, Prabhadevi Ravichandran, S Satish, S Kiran Pradeep, Kathiresan Jeyashree, Preetam Mahajan, Amar N Shah, Richard Kirubakaran, Ajay M V Kumar   +8 more
doaj   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. [PDF]

, 2011
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Developments in the understanding of COPD have led to standard guidelines for diagnosis, treatment, and spirometry assessments, which have in turn ...
James Donohue, Paul Jones, James F Donohue, Paul W Jones, Donohue, JF, Jones, PW   +5 more
core   +1 more source